Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tanya Gurevich is active.

Publication


Featured researches published by Tanya Gurevich.


The New England Journal of Medicine | 2009

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

Ellen Sidransky; Michael A. Nalls; Jan O. Aasly; Judith Aharon-Peretz; Grazia Annesi; Egberto Reis Barbosa; Anat Bar-Shira; Daniela Berg; Jose Bras; Alexis Brice; Chiung-Mei Chen; Lorraine N. Clark; Christel Condroyer; Elvira Valeria De Marco; Alexandra Durr; Michael J. Eblan; Stanley Fahn; Matthew J. Farrer; Hon-Chung Fung; Ziv Gan-Or; Thomas Gasser; Ruth Gershoni-Baruch; Nir Giladi; Alida Griffith; Tanya Gurevich; Cristina Januário; Peter Kropp; Anthony E. Lang; Guey-Jen Lee-Chen; Suzanne Lesage

BACKGROUND Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gauchers disease, among patients with Parkinsons disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinsons disease. METHODS Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinsons disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinsons disease.


European Journal of Neurology | 2003

Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease

J. D. Schaafsma; Yacov Balash; Tanya Gurevich; A. L. Bartels; Jeffrey M. Hausdorff; Nir Giladi

To assess the effect of levodopa on distinct freezing of gait (FOG) subtypes in patients with ‘off’ FOG. Nineteen patients (12 men, mean age 62.0 ± 8.4 years) with Parkinsons disease and clinically significant FOG during ‘off’ states were videotaped whilst walking 130 m during ‘off’ and ‘on’ states. Three independent observers characterized the type, duration, and clinical manifestations and quantified FOG by analyzing the videotapes. Their combined mean scores were used for statistical analysis. The intra‐class correlation coefficient assessed inter‐observer reliability. Wilcoxon and Friedman tests evaluated differences in mean frequencies of FOG characteristics. During ‘off’ states, FOG was elicited by turns (63%), starts (23%), walking through narrow spaces (12%) and reaching destinations (9%). These respective values were only 14, 4, 2 and 1% during ‘on’ states (P < 0.011). Moving forward with very small steps and leg trembling in place were the most common manifestations of FOG; total akinesia was rare. Most FOG episodes took <10 s and tended to be shorter during ‘on’ states. Levodopa significantly decreased FOG frequency (P < 0.0001) and the number of episodes with akinesia (P < 0.001). Distinction amongst FOG subtypes enables evaluation of distinctive therapeutic response. Levodopa helps in reducing the frequency and duration of ‘off’‐related FOG.


Neurology | 2008

Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset

Z. Gan-Or; Nir Giladi; U. Rozovski; C. Shifrin; Serena Rosner; Tanya Gurevich; Anat Bar-Shira; Avi Orr-Urtreger

Background: Mutations in GBA and LRRK2 genes have been implicated in Parkinson disease (PD), particularly in Ashkenazi Jews. Methods: An Israeli Ashkenazi cohort of 420 patients with PD, 333 elderly controls, and 3,805 young controls was screened for eight GBA mutations, which are associated with mild (N370S, R496H) and severe (84GG, IVS2 + 1, V394L, D409H, L444P, RecTL) Gaucher disease. Patients with PD and elderly controls were also genotyped for LRRK2 G2019S. Results: GBA carrier frequency was 17.9% in patients with PD compared to 4.2% in elderly and 6.35% in young controls. The proportion of severe mutation carriers among PD patient GBA carriers was 29% compared to 7% among young controls. Severe and mild GBA mutations increased the risk of developing PD by 13.6- and 2.2-fold, and affected the average age at PD onset (AAO), 55.7 and 57.9 years, compared to 60.7 years in patients without known GBA or LRRK2 mutations. Conclusions: These data demonstrate genotype-phenotype correlations between different GBA mutations and Parkinson disease (PD) risk and AAO in Ashkenazi Jews. Additionally, an earlier AAO was observed in LRRK2 G2019S carrier PD patients. Finally, these data demonstrate that a surprisingly high frequency, more than one third of our patient population, carried a mutation in GBA or LRRK2.


Lancet Neurology | 2013

The natural history of multiple system atrophy: a prospective European cohort study

Gregor K. Wenning; Felix Geser; Florian Krismer; Klaus Seppi; Susanne Duerr; Sylvia Boesch; Martin Köllensperger; Georg Goebel; Karl P. Pfeiffer; Paolo Barone; Maria Teresa Pellecchia; Niall Quinn; Vasiliki Koukouni; Clare J. Fowler; Anette Schrag; Christopher J. Mathias; Nir Giladi; Tanya Gurevich; Erik Dupont; Karen Østergaard; Christer Nilsson; Håkan Widner; Wolfgang H. Oertel; Karla Eggert; Alberto Albanese; Francesca Del Sorbo; Eduardo Tolosa; Adriana Cardozo; Günther Deuschl; Helge Hellriegel

Summary Background Multiple system atrophy (MSA) is a fatal and still poorly understood degenerative movement disorder that is characterised by autonomic failure, cerebellar ataxia, and parkinsonism in various combinations. Here we present the final analysis of a prospective multicentre study by the European MSA Study Group to investigate the natural history of MSA. Methods Patients with a clinical diagnosis of MSA were recruited and followed up clinically for 2 years. Vital status was ascertained 2 years after study completion. Disease progression was assessed using the unified MSA rating scale (UMSARS), a disease-specific questionnaire that enables the semiquantitative rating of autonomic and motor impairment in patients with MSA. Additional rating methods were applied to grade global disease severity, autonomic symptoms, and quality of life. Survival was calculated using a Kaplan-Meier analysis and predictors were identified in a Cox regression model. Group differences were analysed by parametric tests and non-parametric tests as appropriate. Sample size estimates were calculated using a paired two-group t test. Findings 141 patients with moderately severe disease fulfilled the consensus criteria for MSA. Mean age at symptom onset was 56·2 (SD 8·4) years. Median survival from symptom onset as determined by Kaplan-Meier analysis was 9·8 years (95% CI 8·1–11·4). The parkinsonian variant of MSA (hazard ratio [HR] 2·08, 95% CI 1·09–3·97; p=0·026) and incomplete bladder emptying (HR 2·10, 1·02–4·30; p=0·044) predicted shorter survival. 24-month progression rates of UMSARS activities of daily living, motor examination, and total scores were 49% (9·4 [SD 5·9]), 74% (12·9 [8·5]), and 57% (21·9 [11·9]), respectively, relative to baseline scores. Autonomic symptom scores progressed throughout the follow-up. Shorter symptom duration at baseline (OR 0·68, 0·5–0·9; p=0·006) and absent levodopa response (OR 3·4, 1·1–10·2; p=0·03) predicted rapid UMSARS progression. Sample size estimation showed that an interventional trial with 258 patients (129 per group) would be able to detect a 30% effect size in 1-year UMSARS motor examination decline rates at 80% power. Interpretation Our prospective dataset provides new insights into the evolution of MSA based on a follow-up period that exceeds that of previous studies. It also represents a useful resource for patient counselling and planning of multicentre trials. Funding Fifth Framework Programme of the European Union, the Oesterreichische Nationalbank, and the Austrian Science Fund.


Medical Engineering & Physics | 2010

Can an accelerometer enhance the utility of the Timed Up & Go Test when evaluating patients with Parkinson's disease?

Aner Weiss; Talia Herman; Meir Plotnik; Marina Brozgol; Inbal Maidan; Nir Giladi; Tanya Gurevich; Jeffrey M. Hausdorff

INTRODUCTION The Timed Up and Go (TUG) test is a widely used measure of mobility and fall risk in older adults and in Parkinsons disease (PD). We tested the hypothesis that body-fixed accelerometers can provide insight into TUG performance in PD patients. METHODS We examined 17 patients with PD (Hoehn and Yahr score: 2.7+/-0.7; ON state) and 15 age-matched healthy controls; mean ages were 66.8+/-5.9 years, 67.6+/-9.6 years, respectively. Subjects wore a 3D-accelerometer (ADXL330, Analog Devices) on the lower back while performing the TUG test. Sit-to-Stand and Stand-to-Sit times were extracted from the anterior-posterior (AP) signal. Parameters included Sit-to-Stand, Stand-to-Sit durations, amplitude range (Range) and slopes (Jerk). Acceleration median and standard deviation (SD) were also calculated. RESULTS Stopwatch-based TUG duration tended to be higher for the PD patients compared to the control group, although not significantly (p=0.08). In contrast, the TUG duration that was extracted from the acceleration signal was significantly (p<0.02) higher in the PD group compared to the control group. Many acceleration-parameters were also significantly different (p<0.05) between groups; most were not correlated with TUG duration. CONCLUSIONS Accelerometer-derived parameters are sensitive to group differences, indicating that PD patients have poorer mobility during specific aspects of the TUG. In addition to test duration, these measures may serve as complementary and objective bio-markers of PD to augment the evaluation of disease progression and the response to therapeutic interventions.


Neurology | 2007

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease Is there a gender effect

Avi Orr-Urtreger; C. Shifrin; U. Rozovski; Serena Rosner; D. Bercovich; Tanya Gurevich; H. Yagev-More; Anat Bar-Shira; Nir Giladi

Background: Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic determinant of Parkinson disease (PD) identified to date, and have been implicated in both familial and sporadic forms of the disease. The G2019S change in LRRK2 exon 41 has been associated with disease at varying frequencies in Asian, European, North American, and North African populations, and is particularly prevalent among Ashkenazi Jews. Methods: We assessed the occurrence of the LRRK2 G2019S, I2012T, I2020T, and R1441G/C/H mutations in our cohort of Jewish Israeli patients with PD, and determined the LRRK2 haplotypes in 76 G2019S-carriers detected and in 50 noncarrier Ashkenazi patients, using six microsatellite markers that span the entire gene. Results: Only the G2019S mutation was identified among our patients with PD, 14.8% in the Ashkenazi and 2.7% in the non-Ashkenazi patients, and in 26% and 10.6% of the Ashkenazi familial and apparently sporadic cases. The carrier frequencies in the Ashkenazi and non-Ashkenazi control samples were 2.4% and 0.4%. A common shared haplotype was detected in all non-Ashkenazi and half-Ashkenazi carriers and in all full-Ashkenazi carriers tested, except two. Women and patients with a positive family history of PD were significantly over-represented among the G2019S mutation carriers. Age at disease onset was similar in carriers and noncarriers. Conclusions: Our data suggest that the LRRK2 G2019S mutation plays an important role in the causality of familial and sporadic Parkinson disease (PD) in Israel and that gender affects its frequency among patients. Although testing symptomatic patients may help establish the diagnosis of PD, the value of screening asymptomatic individuals remains questionable until the penetrance and age-dependent risk of this mutation are more accurately assessed, and specific disease prevention or modifying interventions become available. GLOSSARY: LRRK2 = leucine-rich repeat kinase 2; PD = Parkinson disease.


Movement Disorders | 2010

Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry†

Martin Köllensperger; Felix Geser; Jean Pierre Ndayisaba; Sylvia Boesch; Klaus Seppi; Karen Østergaard; Erik Dupont; Adriana Cardozo; Eduardo Tolosa; Michael Abele; Thomas Klockgether; Farid Yekhlef; François Tison; Christine Daniels; Günther Deuschl; Miguel Coelho; Cristina Sampaio; Maria Bozi; Niall Quinn; Anette Schrag; C. J. Mathias; Clare J. Fowler; Christer Nilsson; Håkan Widner; Nicole Schimke; Wolfgang H. Oertel; Francesca Del Sorbo; Alberto Albanese; Maria Teresa Pellecchia; Paolo Barone

Multiple system atrophy (MSA) is a Parkinsons Disease (PD)‐like α‐synucleinopathy clinically characterized by dysautonomia, parkinsonism, cerebellar ataxia, and pyramidal signs in any combination. We aimed to determine whether the clinical presentation of MSA as well as diagnostic and therapeutic strategies differ across Europe and Israel. In 19 European MSA Study Group centres all consecutive patients with a clinical diagnosis of MSA were recruited from 2001 to 2005. A standardized minimal data set was obtained from all patients. Four‐hundred thirty‐seven MSA patients from 19 centres in 10 countries were included. Mean age at onset was 57.8 years; mean disease duration at inclusion was 5.8 years. According to the consensus criteria 68% were classified as parkinsonian type (MSA‐P) and 32% as cerebellar type (MSA‐C) (probable MSA: 72%, possible MSA: 28%). Symptomatic dysautonomia was present in almost all patients, and urinary dysfunction (83%) more common than symptomatic orthostatic hypotension (75%). Cerebellar ataxia was present in 64%, and parkinsonism in 87%, of all cases. No significant differences in the clinical presentation were observed between the participating countries. In contrast, diagnostic work up and therapeutic strategies were heterogeneous. Less than a third of patients with documented orthostatic hypotension or neurogenic bladder disturbance were receiving treatment. This largest clinical series of MSA patients reported so far shows that the disease presents uniformly across Europe. The observed differences in diagnostic and therapeutic management including lack of therapy for dysautonomia emphasize the need for future guidelines in these areas.


Movement Disorders | 2008

Red Flags for Multiple System Atrophy

Martin Köllensperger; Felix Geser; Klaus Seppi; Michaela Stampfer‐Kountchev; Martin Sawires; Christoph Scherfler; Sylvia Boesch; Joerg Mueller; Vasiliki Koukouni; Niall Quinn; Maria Teresa Pellecchia; Paolo Barone; Nicole Schimke; Richard Dodel; Wolfgang H. Oertel; Erik Dupont; Karen Østergaard; Christine Daniels; Günther Deuschl; Tanya Gurevich; Nir Giladi; Miguel Coelho; Cristina Sampaio; Christer Nilsson; Håkan Widner; Francesca Del Sorbo; Alberto Albanese; Adriana Cardozo; Eduardo Tolosa; Michael Abele

The clinical diagnosis of multiple system atrophy (MSA) is fraught with difficulty and there are no pathognomonic features to discriminate the parkinsonian variant (MSA‐P) from Parkinsons disease (PD). Besides the poor response to levodopa, and the additional presence of pyramidal or cerebellar signs (ataxia) or autonomic failure as major diagnostic criteria, certain other clinical features known as “red flags” or warning signs may raise the clinical suspicion of MSA. To study the diagnostic role of these features in MSA‐P versus PD patients, a standardized red flag check list (RFCL) developed by the European MSA Study Group (EMSA‐SG) was administered to 57 patients with probable MSA‐P and 116 patients with probable PD diagnosed according to established criteria. Those red flags with a specifity over 95% were selected for further analysis. Factor analysis was applied to reduce the number of red flags. The resulting set was then applied to 17 patients with possible MSA‐P who on follow‐up fulfilled criteria of probable MSA‐P. Red flags were grouped into related categories. With two or more of six red flag categories present specificity was 98.3% and sensitivity was 84.2% in our cohort. When applying these criteria to patients with possible MSA‐P, 76.5% of them would have been correctly diagnosed as probable MSA‐P 15.9 (±7.0) months earlier than with the Consensus criteria alone. We propose a combination of two out of six red flag categories as additional diagnostic criteria for probable MSA‐P.


Annals of Neurology | 2011

Gait alterations in healthy carriers of the LRRK2 G2019S mutation

Anat Mirelman; Tanya Gurevich; Nir Giladi; Anat Bar-Shira; Avi Orr-Urtreger; Jeffrey M. Hausdorff

To test for an association between the LRRK2‐G2019S mutation and gait, we studied 52 first‐degree relatives of patients with Parkinsons disease (PD) who carry this mutation. An accelerometer quantified gait during usual‐walking, fast‐walking, and dual‐tasking. Noncarriers (n = 27) and carriers (n = 25) were similar with respect to age, gender, height, and gait speed during all conditions. During dual‐tasking and fast‐walking, gait variability and the amplitude of the dominant peak of the accelerometer signal were significantly altered among the carriers. These findings support the possibility of previously unidentified, presymptomatic motor changes among relatives who have an increased risk of developing PD. Ann Neurol 2010


Movement Disorders | 2006

Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA study group (EMSA SG)

Felix Geser; Gregor K. Wenning; Klaus Seppi; Michaela Stampfer‐Kountchev; Christoph Scherfler; Martin Sawires; C. Frick; Jean-Pierre Ndayisaba; Hanno Ulmer; Maria Teresa Pellecchia; Paolo Barone; Ht Kim; J Hooker; N Quinn; Adriana Cardozo; E. Tolosa; Michael Abele; Thomas Klockgether; Karen Østergaard; Erik Dupont; Nicole Schimke; Karla Eggert; Wolfgang H. Oertel; Ruth Djaldetti; Werner Poewe; Richard Dodel; François Tison; Imad Ghorayeb; Pierre Pollak; M Kölensperger

The disease‐specific Unified Multiple System Atrophy Rating Scale (UMSARS) has been developed recently and validated for assessing disease severity in multiple system atrophy (MSA). Here, we aimed at (1) assessing rates of disease progression in MSA and (2) validating UMSARS for sensitivity to change over time. Impairment was assessed at two time points 12 months apart using UMSARS Part I (historical review), UMSARS Part II (motor examination), as well as measures of global disease severity, including UMSARS Part IV, Hoehn and Yahr (HY) Parkinsons disease staging, Schwab England Activities of Daily Living (SE ADL), and a three‐point global Severity Scale (SS3). Fifty patients (male:female ratio, 1:0.9; possible MSA, 16%; probable MSA, 84%; MSA‐parkinsonian, 58%; MSA‐cerebellar, 42%) were assessed twice with an interval of 12.3 months. UMSARS II scores progressed by 57.3% (P < 0.0001) and UMSARS I scores by 35.6% (P < 0.0001) in relation to the respective baseline scores with no differences between motor subtypes, diagnostic categories and gender. Significant inverse correlations between (1) UMSARS I or UMSARS II progression and (2) baseline disability measures (i.e., the respective UMSARS or SS3 scores) and disease duration were found. Furthermore, the increases in HY staging, SE ADL and SS3 correlated significantly with UMSARS I, UMSARS II, and UMSARS IV progression. This report is the first prospective study showing rapid annual UMSARS rates of decline in MSA. Our data contribute to the ongoing validation process of UMSARS, and they facilitate the planning and implementation of future neuroprotective intervention trials.

Collaboration


Dive into the Tanya Gurevich's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anat Bar-Shira

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yacov Balash

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge